#1246 Weekly Diabetes News 7/1/24

July 5, 2024Scott Benner

Topics include the US launch of Medtronic's MiniMed 780G system, promising research from Johns Hopkins on a monoclonal antibody for type 1 diabetes, and gene therapy advancements by Fractal Health. Scott also discusses legislative news on CGM access in Illinois and early developments in oral insulin formulations.

You can always listen to the Juicebox Podcast here but the cool kids use: Apple Podcasts/iOS - Spotify - Amazon Music - Google Play/Android - iHeart Radio - Radio Public, Amazon Alexa or wherever they get audio.

+ Click for EPISODE TRANSCRIPT

DISCLAIMER: This text is the output of AI based transcribing from an audio recording. Although the transcription is largely accurate, in some cases it is incomplete or inaccurate due to inaudible passages or transcription errors and should not be treated as an authoritative record. Nothing that you read here constitutes advice medical or otherwise. Always consult with a healthcare professional before making changes to a healthcare plan.

Scott Benner 0:00
Hello friends and welcome to episode 1246 of the Juicebox Podcast

I'm back with another quick episode to catch you up on what's in the news for type one diabetes this week this is for the week of July 1. Nothing you hear on the Juicebox Podcast should be considered advice, medical or otherwise, always consult a physician before making any changes to your health care plan.

sup everybody, I'm back to read you the news about diabetes. Nice to me, I'm just I scour the internet for you. I find stuff. It's interesting to me, I come here and I tell you about it. And 15 minutes later, you've got all that stuff in your head without any of that pesky reading. Hey, if you want to save 30% off of your entire order at cozy earth.com Just use the offer code juice box at checkout. And of course, when you place your first order for ag one with my link, you'll get five free travel packs and a free year supply of vitamin D. Drink ag one.com/juicebox if you have type one diabetes, and you're from the US or you're the caregiver of someone with type one, please go to T one D exchange.org/juicebox. and complete the survey completing the survey helps type one diabetes research and it only takes a few minutes. Before we get started, let me tell you about the 2025 Juice cruise. Now what is that exactly? Well, I'm going on a cruise. And I'm inviting all of you to come with me. This is going to happen in June of 2025. But if you register by August 1 2024, you're going to receive a $25 onboard credit per stateroom. This Cruise is great for you if you have a family with children with type one if you're an adult with type one or anywhere in between. I got a note the other day and said I have type two diabetes. I'm a listener and I want to come I was like absolutely Let's go. Everybody is welcome. Bring the kids bring yourself bring the fam. Let's get out in the sun meet each other really experienced community one on one and have a great time. Maybe you just want to meet other Juicebox Podcast listeners. Maybe you want to meet other people that you know from the private Facebook group or perhaps you just have never met another person with diabetes and this is your chance. We're gonna fill that boat with beeping. Understand, it's gonna be very real. What is that? Somebody's blood sugar's high. This Cruise is on the Royal Caribbean International's mariners of the sea. It departs Galveston, Texas on Monday, June 23. It's a five night trip with ports of call in Galveston Costa Maya and Cozumel. Now for two of the days of the trip, there'll be talks, I'll be giving talks meet and greets Q and A's, we're going to bring on some special guests to talk to and right now I'm going to start to reach out to advertisers of the show to see if they'd like to send out customer service people so that you actually have somebody from specific companies to ask questions of I thought that was kind of a nice idea. I'm working on that right now. I don't know if that's gonna happen. It's up to the companies. But we'll find out. If you want to learn more, go to the link or text Suzanne at 817-928-4930. That's poor Suzanne who's about to get a lot of texts. She's running the whole, you know, travel side of this whole thing. The Scotty side of it, if you go to the link, you'll be able to see the different state rooms, the complete charges that are you know, necessary per person, you'll understand what you're talking about before you reach out to Suzanne, or if you just want to reach out to her and get the conversation started. I'm sure she'd be thrilled to talk to you. All right, juicebox podcast.com, or link in the show notes or text Suzanne, and I'll see you on the ship in June. I'm very, very excited to meet everyone. I hope you can come bring the family. Now on to the news. So I searched a little bit did some looking around poking around because ADA is at fourth Scientific Sessions was last week. So I figured there's got to be some takeaways from ADA. Right. The American diabetes Association holds a big conference, there must be news. Here's what I found some interesting stuff. And some stuff that you just kind of expect companies are like our thing is good. Like, okay, well we know about that. That's not actually news. We know you think you think is good, and it probably is but we're looking for new stuff to talk about not just you know, we did a study and you know, there's less hypoglycemia if you were an automatic insulin delivery system. Yeah, thanks. We know how about this one I'm going to start here. Medtronic is launching the mini med seven ATG system in Oh, the US us launch of the mini med seven ATG system. The guardian for sensor that's interesting. includes advanced hybrid closed loop technology for automated insulin delivery. Sounds like they're getting their thing into the US. What else here? There are new therapeutic targets for diabetes discussed? Oh, really? I can't wait for that. Yeah, I can't wait for the establishment to realize that maybe your agency should be lower than seven. Boy, a lot of this is probably just going to irritate me, it's going to be stuff we've been talking about for, you know, 510 years on the podcast, where they're like, we've done a study and we've figured it out. There's health disparities in communities. How about that? Who knew? But this is just me being sarcastic with the news. I didn't expect that. But here we are. This is just, this is just research with mice at this point. But it's interesting enough. Where's this over at Johns Hopkins, a drug named M A, B 43. It's a monoclonal antibody. It's only they're doing mice studies right now, but prevents and reverses type one diabetes onset in mice potential for long term use with minimal side effects, beta cells begin reproducing an inflammation decreases. I'm excited about anybody who's looking into inflammation in the pancreas. Very interesting, led by a PhD here. Not a lot more than that. But, you know, I don't like to get too excited about things that work in mice, because they very often don't work in people. But still, I like the direction of that. Now, here's something I actually did find really interesting. I think this is more around type two. But it's very, it's very, very interesting. And here's why. Here's the overview of it. A recent study explored the effects of a single dose of GLP, one based gene therapy, on obesity and diabetes management in mice. Again, mice, but, you know, this is kind of interesting. The therapy is designed to deliver a gene encoded encoding GLP one, which is a hormone involved in blood sugar regulation, and this gets delivered directly to the pancreas. The mice were divided into three groups one receiving gene therapy, one receiving daily semaglutide injections, and one receiving a placebo. During the duration to the initially, excuse me initially followed for four weeks with a follow up period extending to eight weeks for some groups. Now here's the key findings. There was weight and fat reduction, the mice treated with the gene therapy experienced at 21% reduction in fat mass compared to a 16% with the semaglutide After four weeks, ooh. And after eight weeks that gene therapy maintained a 17% reduction in fat mass, even after semaglutide withdrawal. While the placebo group saw no significant effect, no significant change. Hmm. Significant improvements in fasting glucose and insulin levels were observed in the gene therapy and semaglutide groups at both four and six weeks. The third, the therapy resulted in a 36% reduction in total cholesterol and a 51% reduction in LDL cholesterol compared to placebo after two months. And they're saying here the potential is this gene therapy could offer a long term single dose treatment option for managing obesity and diabetes. It aims to provide durable weight loss, and improve metabolic control without the need for continuous medication. So it's something about listen, I'm no surgeon here, or researcher. But what I'm hearing is you take the GLP one, and you magic mix it somehow in a gene therapy situation. And then maybe you're re I don't want to speak for this thing. But maybe you're recoding how things are working. Anyway, it looks like a company called fractal health. They plan to progress the therapy through preclinical development and initiate first in human clinical studies in the first half of 2025. That gets a clap for me. Let's go fractal health looks like they're calling this drug. Is it read Juvia investor's clinical studies, our company I might reach out to them to get somebody on the podcast here. I mean, unless they're listening, and then just please send me an email. I have a lot of time for this. I don't have a lot of time to be sending emails. I'm very busy. Yeah, I don't know if they've got a PR I'll look through there. I'm gonna hold on to this. I might, I might, I might reach out to them. That's not a bad idea. What else do we have here? Did the Hopkins thing. Health Disparities, there's health disparities and communities they figured it out. They just did a research study. It only took a couple of years and they came back and they said things are not fair. Look at you got it. Let's see. Don't you know tandems got that Moby pump now? On the pod five works with Dexcom G seven.

I heard some news from ever since but I can't I gotta make sure I get the details. Right before I bring it to you. Maybe you'll hear about that next week. This is kind of local, but I find this very encouraging. Illinois has passed legislate legislation legislation, expanding access to continuous glucose monitors for Medicaid benefit beneficiaries. That's excellent. This move is praised by the American diabetes Association. It's praised by me too. That's good and more people should be doing that and more states 1,000,000% All right, kids. There's some older stuff here. It's not new news, but it's still stuff that pops up when I'm when I'm talking there's an oral insulin formulation developed by the Artic University of Norway that could potentially eliminate the need for insulin injections. That'd be cool. Very, very early on, but keep working on that for sure. And there was something here about let me find it. Let me find it intermittent fasting. Okay, I got it. This is a UIC research initiative on intermittent fasting with type one diabetes. The study lead Christa Verde, hey, Krista. What's up? You're famous professor of nutrition at the University of Illinois, Chicago. The focus of the study was examining the safety and effectiveness of time restricted eating a form of intermittent fasting for individuals with type one diabetes. I thought this was really interesting. She found there were no adverse reactions. How about that? She's talking about hypoglycemia, diabetic ketoacidosis. In the reviewed studies, participants experience weight loss and lowered average blood sugar levels in some cases. It's like there was a pilot study here. It's still ongoing comparing time restricted eating to calorie counting, and a control group was 60 participants. The recommendation after the study was a patient should consult with their doctors and well that's not great, Krista, but I think what you're really taken from this is somebody's out there doing a study about fasting with type one diabetes, where a lot of you would say, oh, you know, if I fast my blood sugar is gonna get low, where I would say, if your settings were good, you could not eat for quite some time without experiencing a low blood sugar. This is the takeaway here, right? Because people are always wondering like, how do I exercise my blood sugar voice false exercise without any active insulin. That doesn't mean you don't have your Basal going, but it's a really well timed Basal, a well considered Basal, so it's not dragging you lower. I brought this up mainly to remind you that you can exercise fasting and that that's probably a way for you to keep from having a low blood sugar while you're exercising if you have type one, but also Krista viraday. Professor, if you'd like to come on the podcast, give me a shout. I'd love to talk about this a little more. I think it's very interesting and timely, and I think it's important for people living with type one diabetes. Alright, that's it for Scotty reads you the news this week. Don't forget the juice crews link in the show notes link at juicebox podcast.com. And of course, how to do it again. Of course you could just text Suzanne at 817-928-4930 and say I want to know more about the juice cruise and Suzanne will go Why is my phone blown up like this but that's between you and Suzanne. I will not be giving you my phone number and also be very nice to Suzanne. She's lovely. She has type one diabetes. She's a travel agent and this was her brainchild. And she's doing the lion's share of the work. She's a lovely lady, and she'd love to get you set up on the cruise and of course I'd love to see you there.